Moderna says FDA delayed RSV vaccine approval to end of May

Moderna announced that the FDA has postponed the approval of its RSV vaccine until the end of May, citing "administrative constraints." Initially expected by Sunday, the FDA has not identified any concerns regarding the vaccine's safety, efficacy, or quality. The delay is a key moment for Moderna as it seeks to diversify its portfolio beyond its COVID-19 vaccine, with the advisory panel review scheduled for late June.